In silico fragment-based discovery of DPP-IV S1 pocket binders

被引：39

作者：

Rummey, C

Nordhoff, S

Thiemann, M

Metz, G

机构：

[1] Santhera Pharmaceut, Computat Discovery, D-69120 Heidelberg, Germany

[2] Santhera Pharmaceut, Med Chem, D-69120 Heidelberg, Germany

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 05期

关键词：

dipeptidyl peptidase-IV inhibitors; molecular anchor; fragment-based discovery; virtual screening; docking;

D O I：

10.1016/j.bmcl.2005.11.038

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Dipeptidyl peptidase IV is a clinically validated target for type-2 diabetes and belongs to a family of peptidases with a quite unique post-proline cleavage specificity. Known inhibitors contain a limited number of molecular anchors occupying the small prototypical S1 pocket. A virtual screening approach for such SI-binding fragments was carried out using FlexX docking to evaluate its potential to confirm known and find novel compounds. Several low molecular weight inhibitors exhibiting activities in the micromolar range could be identified as starting points for structure-based design. (C) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1405 / 1409

页数：5

相关论文

共 31 条

[1] Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes [J].

Augustyns, K ;

Van der Veken, P ;

Senten, K ;

Haemers, A .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (04) :499-510

[2] Comparison of automated docking programs as virtual screening tools [J].

Cummings, MD ;

DesJarlais, RL ;

Gibbs, AC ;

Mohan, V ;

Jaeger, EP .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :962-976

[3] The crystal structure of dipeptidyl peptidase IV(CD26) reveals its functional regulation and enzymatic mechanism [J].

Engel, M ;

Hoffmann, T ;

Wagner, L ;

Wermann, M ;

Heiser, U ;

Kiefersauer, R ;

Huber, R ;

Bode, W ;

Demuth, HU ;

Brandstetter, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) :5063-5068

[4] Molecular recognition: the fragment approach in lead generation [J].

Fattori, D .

DRUG DISCOVERY TODAY, 2004, 9 (05) :229-238

[5] Druggability indices for protein targets derived from NMR-based screening data [J].

Hajduk, PJ ;

Huth, JR ;

Fesik, SW .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) :2518-2525

[6] Flexible docking under pharmacophore type constraints [J].

Hindle, SA ;

Rarey, M ;

Buning, C ;

Lengauer, T .

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (02) :129-149

[7]

Holst Jens Juul, 2004, Expert Opin Emerg Drugs, V9, P155, DOI 10.1517/eoed.9.1.155.32952

[8] (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Kim, D ;

Wang, LP ;

Beconi, M ;

Eiermann, GJ ;

Fisher, MH ;

He, HB ;

Hickey, GJ ;

Kowalchick, JE ;

Leiting, B ;

Lyons, K ;

Marsilio, F ;

McCann, ME ;

Patel, RA ;

Petrov, A ;

Scapin, G ;

Patel, SB ;

Roy, RS ;

Wu, JK ;

Wyvratt, MJ ;

Zhang, BB ;

Zhu, L ;

Thornberry, NA ;

Weber, AE .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :141-151

[9] Docking and scoring in virtual screening for drug discovery: Methods and applications [J].

Kitchen, DB ;

Decornez, H ;

Furr, JR ;

Bajorath, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) :935-949

[10]

Klebe Gerhard, 2004, Drug Discov Today Technol, V1, P225, DOI 10.1016/j.ddtec.2004.10.010

← 1 2 3 4 →